uniQure N.V. (QURE)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Matthew Craig Kapusta CPA
|
CEO & Executive Director | 1.05M | 9.38M | 1972 |
|
Mr. Christian Klemt
|
CFO, Principal Financial Officer & GM of Amsterdam Site | 759.95k | 945.14k | 1973 |
|
Dr. Jeannette Potts J.D., Ph.D.
|
Chief Legal & Compliance Officer and Corporate Secretary | 712.83k | -- | 1962 |
|
Dr. Walid Abi-Saab M.D.
|
Chief Medical Officer | 945.28k | -- | 1965 |
|
Prof. Hugo Katus
|
Chairman of Scientific Advisory Board and Managing Director of UniQure-Germany | -- | -- | -- |
|
Dr. Amin Abujoub Ph.D.
|
Chief Technical Operations Officer | -- | -- | -- |
|
Mr. Richard Porter Ph.D.
|
Chief Business & Scientific Officer | 732.17k | -- | 1968 |
|
Ms. Chiara Elizabeth Russo
|
Senior Director of Investor Relations | -- | -- | -- |
|
Dr. Tamara Tugal Ph.D., MBA
|
Business Development Director | -- | -- | -- |
|
Ms. Erin Boyer
|
Chief People & Culture Officer | -- | -- | -- |
uniQure N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 221
Description
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. The company also develops AMT-260, which is in Phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in Phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
Corporate Governance
Upcoming Events
November 4, 2026 at 12:30 PM UTC
uniQure N.V. Earnings Date
